SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

VETmAb Biosciences Reports Positive Canine Inflammatory Enteropathy Proof-of-Concept Results

The company said 77.8% of dogs in the VMB-C001a group were treatment successes, compared with 30.0% in the comparison group.

Related stories